Better Late Than Never: “Breakthrough” Status Aided Sovaldi’s On-Time Approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Although Gilead’s hepatitis C drug picked up the “breakthrough therapy” moniker with just two months left in the NDA review cycle, the designation enabled FDA staff to analyze new VALENCE and PHOTON-1 trial data and still approve sofosbuvir by the PDUFA goal date.
You may also be interested in...
How Sovaldi Won A Broad Label: Emerging Data Swayed Reluctant FDA
Agency reviewers were skeptical about awarding Gilead’s sofosbuvir an indication for use in combination with other, unspecified agents for treating chronic hepatitis C – a game-changing approach for the fast-evolving field. However, data submitted late in the review process from two ongoing Phase III studies convinced FDA that a broad indication was justified.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.
Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works
FDA Commissioner Robert Califf tells House appropriations subcommittee chair the agency will 'consider any information that may be available' on off-label use of puberty blockers for gender dysphoria before making a regulatory decision.